Regeneron Announces $3B Share Repurchase Program
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program of up to $3 billion of the Company's outstanding common
Europe Approves Regeneron – Roche’s COVID-19 Antibody Cocktail
The European Commission (EC) has approved Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve…
Regeneron Pharmaceuticals’ Co-Developed Antibody Cocktail Approved By European Commission To Treat And Prevent COVID-19
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has approved the casirivimab and imdevimab antibody cocktail, known as REGEN-COV® in the U.S.
Booster and Renewable Energy Group Enter Strategic Partnership To Offer Mobile Delivery Of Sustainable Fuels
Booster, the tech-enabled energy delivery service, and Renewable Energy Group (REG) (NASDAQ:REGI), a leading producer and provider of lower carbon fuels, today announced a first-of-its-kind partnership to
When Winning Streaks Stop: Trying To Beat The Market By Buying Stocks Like Tesla
Teslas getting charged in a Wawa parking lot last month. Photo via author.
When Winning Streaks Stop
Regeneron-Roche’s COVID-19 Treatment Shows Long Term Benefit After Single Dose
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200…
Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro
Does crime pay?
Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition and greed take them in the wrong direction.
SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $850
SVB Leerink analyst Geoffrey Porges maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $798 to $850.
Benchmark Downgrades Regeneron Pharmaceuticals to Hold
Benchmark analyst Aydin Huseynov downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Buy to Hold.
HC Wainwright & Co. Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $844
HC Wainwright & Co. analyst Michael King maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $842 to $844.